Document is current
Any future updates will be listed below
-
Authors
Maia-Silva, Diogo
Cunniff, Patrick J. https://orcid.org/0000-0002-7761-6810
Schier, Allison C.
Skopelitis, Damianos
Trousdell, Marygrace C. https://orcid.org/0000-0002-4824-7040
Moresco, Philip https://orcid.org/0000-0003-4020-959X
Gao, Yuan https://orcid.org/0000-0003-3393-2376
Kechejian, Vahag
He, Xue-Yan https://orcid.org/0000-0001-5423-5997
Sahin, Yunus https://orcid.org/0000-0002-2721-6683
Wan, Ledong https://orcid.org/0000-0002-2450-3986
Alpsoy, Aktan https://orcid.org/0000-0002-8940-8277
Liverpool, Jynelle
Krainer, Adrian R. https://orcid.org/0000-0001-9024-9501
Egeblad, Mikala
Spector, David L. https://orcid.org/0000-0003-3614-4965
Fearon, Douglas T.
dos Santos, Camila O. https://orcid.org/0000-0002-3999-9523
Taatjes, Dylan J.
Vakoc, Christopher R. https://orcid.org/0000-0002-1158-7180
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA013106-Project 1)
- License Information
-
More Information
Article History
Received: 19 April 2023
Accepted: 7 May 2024
First Online: 17 June 2024
Competing interests
: C.R.V. has received consulting fees from Flare Therapeutics, Roivant Sciences and C4 Therapeutics; has served on the advisory boards of KSQ Therapeutics, Syros Pharmaceuticals and Treeline Biosciences; has received research funding from Boehringer-Ingelheim and Treeline Biosciences; and owns stock in Treeline Biosciences. D.J.T. is a member of the SAB at Dewpoint Therapeutics. D.L.S. is a member of the Scientific Advisory Board of Flamingo Therapeutics and Amaroq Therapeutics. A.R.K. is a Founder, Director and Chair of the SAB of, and owns stock in, Stoke Therapeutics; serves on the SABs of Skyhawk Therapeutics, Envisagenics and Autoimmunity BioSolutions; and is a consultant for Biogen and Seed Therapeutics. The other authors declare no competing interests.
